🔬 I’ll be at #ASCO25 to discuss the differential genomic landscape of ER-low vs ER+ and ER- m+ #breastcancer. Join the conversation at Poster Board 50 on 6/2/25, 9:00 AM–12:00 PM! #bcsm @danafarber.bsky.social @danafarbernews.bsky.social @ascocancer.bsky.social www.asco.org/abstracts-pr...

Try and play with it. All the feedback will be welcomed by @ascocancer.bsky.social and @newsfromgoogle.bsky.social ! ASCO Guidelines Assistant is available to anyone with an ASCO account until June 8, 2025. After this date, use of this tool is an exclusive benefit for ASCO members.

🚨NEW @ascocancer.bsky.social #EduBook chapter: @hoperugo.bsky.social, @stolaney1.bsky.social & I unpack the most debated trial design issues in m+ #BreastCancer —suboptimal control arms, crossover challenges, post-progression tx, non-inferiority margins, patient selection. ➡️ shorturl.at/nZWdI #bcsm

In medio stat virtus

Scientific publishers are under siege by distant buyers, flipping journals to #OpenAccess and raising APCs. @Nature article explains the game: “Invasion of the ‘journal snatchers’: the firms that buy science publications and turn them rogue” www.nature.com/articles/d41...

“Education is one of the few forces powerful enough to break the cycle of #poverty. It gives children born into hardship the tools to rewrite their story—and shape a future of their own making.”

Don't miss this newly published review discussing recent advances in immune checkpoint inhibitors for #TripleNegativeBreastCancer. 🔓 pubmed.ncbi.nlm.nih.gov/40196378/ @ccortimd.bsky.social @stolaney1.bsky.social #TNBC #BreastCancer

www.sciencedirect.com/science/arti... If your business model is still selling algorithms, please stop. The accuracy of models is limited in time and space. The pursuit of generalizability is misguided. AI should be local, iterative, reflective and reflexive.

"Global disparities in artificial intelligence-based mammogram interpretation for breast cancer: A scientometric analysis of representation, trends, and equity" shorturl.at/Q7xFo .

From #immunotherapy (IO) failures to new strategies & biotech innovations in metastatic TNBC, to IO timing, chemo backbones, & novel approaches in the early stage. All this & more in our latest review on immune checkpoint inhibitors in #TNBC. shorturl.at/izpbe @dfcibreastonc.bsky.social

Great to stop by #USCAP25 this afternoon to support our team’s work using #MachineLearning to characterize the tumor microenvironment in post-surgical #TNBC specimens after neoadjuvant chemo. @dfcibreastonc.bsky.social @uscap.org

AI-generated content floods literature with poor-quality publications, casts doubt on metrics, @science.org and Retraction Watch investigation finds. www.science.org/content/arti...

Merry Christmas to all. Health truly is our most precious gift - It’s not just a cliché. For some, this season means remembering a loved one, facing a tough diagnosis, starting a new treatment, or getting difficult scan results. My heart is with you. ❤️

🚨 NY Gov. Kathy Hochul signs bill mandating private insurers cover scalp cooling systems starting Jan 1, 2026. 👏 First state to do so—hopefully paving the way for universal access. #CancerCare #HealthEquity #bcsm shorturl.at/AXNdm

Great work showing half of patients with metastatic relapse after adjuvant abemaciclib have loss of estrogen expression. Biopsy remains critical. #sabcs24 @oncbrothers.bsky.social

Post-hoc TAILORx analysis: In HR+/HER2-, LN- breast cancer w/ RS ≥31, anthracycline (T-AC) improved 5-year DRFI (96% vs 91%, aHR 0.32, p=0.009) and DRFS vs TC. Benefit strongest in tumors >2cm, increasing with RS Results are alligned w/ other MammaPrint High 2 results @oncoalert.bsky.social

Join us in Row 10 to see our poster on outcomes in HER2+ & TNBC pts treated with neoadjuvant tx! Key findings: ✅ pCR linked to better outcomes ✅ 3-yr RFS/OS varied by cT, cN, & subtype at dx ✅ In RD pts, cT, cN, & subtype stayed prognostic, but not in pCR pts (few events) #SABCS24 #bcsm

Thank you all for stepping by and chatting with me yesterday. Thanks to @dfcibreastonc.bsky.social , my mentor @stolaney1.bsky.social , and all the co-authors for this great opportunity 😊 #SABCS2024 @sabcs.bsky.social

Don’t miss #SABCS24 Clinical Controversies Session on: Omission of Axillary Staging in ER-Positive #BreastCancer - Implications on Adjuvant Therapies, where Dr. Elizabeth Mittendorf will discuss the current data.

Please join us for the poster session today at 12.30PM! Our work on patients who experienced recurrence on adjuvant abemaciclib is in Row 9, right in front of the exhibitors. We look forward to chatting with you! @sabcs.bsky.social @dfcibreastonc.bsky.social

Meet Chiara Corti, MD(@ccortimd.bsky.social)! She came to Dana-Farber from IEO and the Università degli Studi di Milano. Now a #DFCIAdvancedFellow her research focuses on optimizing #BreastCancer treatment via tumor & microenvironment profiling and leveraging AI to streamline clinical operations.

Biomarker analyses of KN-522 shows most markers (T-cell GEP, HRD, HER2 signaling, PTEN, TNBC subtype) were prognostic but not predictive High TMB showed a signal for pembro benefit, but only in 8% of pts Predictive biomarkers for ICI in early TNBC are urgently needed! @oncoalert.bsky.social

Don’t miss tomorrow’s poster session, with a stellar team! Honored to present with @dfcibreastonc.bsky.social #SABCS2024 @sabcs.bsky.social

Dr. Dos Santos presents data around how the breast is changed during pregnancy...and persists (not just during pregnancy)! 🤰 May explain why parity and age impacts breast cancer risk 📊. Early pregnancy ⬇️ breast cancer risk by 30-40% #SABCS24 @sabcs.bsky.social @oncoalert.bsky.social #bcsm

Hello, #MedSky community! We’re excited to begin our Bluesky journey. Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:

Finally also the amazing @dfcibreastonc.bsky.social group has joined @bsky.app ! Follow this account 👆🏻 for the latest news regarding #breastcancer meetings, clinical trial related info, new research coming out and much more !

We are looking forward to this year's San Antonio Breast Cancer Symposium which starts on December 10. Take a look at the full program for this important meeting featuring the latest research on breast cancer. sabcs.org/FullProgram #SABCS24 #breastcancer

Thrilled to see this labor of love finally out! Many thanks to the amazing and incredibly patient @myESMO publishing team for their support in bringing together diverse perspectives throughout the drafting, editing, and proofreading process. #bcsm #ESMO oncologypro.esmo.org/education-li...

One of the reasons why epistemic diversity is key to good teams and collaborations

It’s the International Day to End Violence against Women and Girls! 1 in 3 girls and women around the world experience physical and/or sexual violence by: A husband A boyfriend An intimate partner A lover A parent A relative A colleague A boss A stranger bit.ly/3gy8pfq #NoExcuse

Thank you, Elia, for appreciating our work!! ☺️

I am truly grateful for the opportunity to bring together with this paper the amazing people I have had the privilege of working with in the field of #immunotherapy. #bcsm #breastcancer #OpenAccess www.cancertreatmentreviews.com/article/S030...

An incredible day of lectures at @DanaFarber ! Dr. Disis delivered a phenomenal noon lecture on her pioneering work in cancer vaccines. 🙏🏻 #bcsm #breastcancer #dfci #cancervaccine

Incredibly grateful for the opportunity to attend the 6th Annual Carolyn Kaelin Lecture with Dr. Kelly K. Hunt as guest speaker. A true pioneer and living legend in #breast #surgicaloncology and collaborative efforts in the field. #bcsm #BrighamWomens #DFCI #danafarber #breastcancer

Dopo il Guardian (che ha lasciato X per approdare su Bluesky) anche il Centro Europeo per il controllo delle malattie ECDC valuta di lasciare la piattaforma. Il livello di disinformazione è tale che anche le più grandi istituzioni sanitarie alzano bandiera bianca. www.politico.eu/article/euro...

Great work, thank you - starter packs were super helpful for me when I came over but weren't many hem/onc then. Here are a couple more: @joshdragomd.bsky.social @eschattner.bsky.social @ccortimd.bsky.social @antoniopassaro.bsky.social @rsm2800.bsky.social @leonidasplatan1.bsky.social

Ok #OncSky and #BCSM #SABCS24 is coming up! We used to post updates of important studies and abstracts we find practice changing on X, but I’d love it if we could do that here. Who wants to join me in this?

“We need #women who are so strong they can be #gentle, so #educated they can be #humble, so fierce they can be #compassionate, so #passionate they can be #rational, and so disciplined they can be #free.” ― Kavita N. Ramdas